Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMPOU5H)

Drug Name

ENASIDENIB MESYLATE Drug Info

Synonyms

UNII-UF6PC17XAV; AG-221 mesylate; Enasidenib (mesylate); UF6PC17XAV; Enasidenib mesylate [USAN]; Enasidenib mesylate (USAN); Enasidenib mesilate; Enasidenib methanesulfonate; Idhifa (TN); SCHEMBL16448052; HY-18690A; CS-7541

Indication

Disease Entry	ICD 11	Status	REF
Acute myeloid leukaemia	2A60	Approved	[1]

Cross-matching ID

PubChem CID: 90480031
CAS Number: CAS 1650550-25-6
TTD Drug ID: DMPOU5H

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Isocitrate dehydrogenase (IDH)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AG-221	DMS0ZBI	Acute myelogenous leukaemia	2A41	Phase 3	[2]
AG-881	DMIE1WY	Glioma	2A00.0	Phase 3	[3]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Isocitrate dehydrogenase (IDH)	TTDTWV0	IDHC_HUMAN; IDHP_HUMAN; IDH3A_HUMAN; IDH3B_HUMAN; IDH3G_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
2	New Developments in the Pathogenesis and Therapeutic Targeting of the IDH1 Mutation in Glioma. Int J Med Sci. 2015; 12(3): 201-213.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)